BioMarin Pharmaceutical’s (NASDAQ:BMRN) “Buy” Rating Reaffirmed at Cowen
Cowen restated their buy rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research report report published on Monday, December 16th, AnalystRatings.com reports. Cowen currently has a $150.00 price target...








